{
    "clinical_study": {
        "@rank": "116120", 
        "acronym": "PRAS-AM", 
        "arm_group": {
            "arm_group_label": "10 mg, 30 mg", 
            "arm_group_type": "Other", 
            "description": "To compare PKPD of prasugrel 10 or 30 mg, 4 subjects will be given 10 mg of prasugrel (one tablet of 10 mg of Effient) on day 1 as a single oral dose and another 4 subjects will be given 30 mg of prasugrel (3 tablets of 10 mg of Effient) on day 1 as a single oral dose."
        }, 
        "brief_summary": {
            "textblock": "An open label, parallel study to characterize the pharmacokinetics and pharmacodynamics of\n      Prasugrel 30 mg or 60 mg in healthy male adult subjects"
        }, 
        "brief_title": "Clinical Trial to Characterize Pharmacokinetic-pharmacodynamic (PKPD) of Prasugrel 10 mg or 30 mg in Healthy Volunteers", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "1. Screening\n\n        2. Enrollment and treatment randomization\n\n        3. Confinement to Research Unit from day - 1 to day 2\n\n        4. Outpatient visit : 2 times ( 48 and 73 hours after dosing)\n\n        5. Drug administration : Overnight Fasting\n\n        6. Blood sampling for PK, PD and genotyping\n\n             1. PK: up to 24 hours after dosing\n\n             2. PD: up to 72 hours after dosing"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  male aged 19 to 45 years\n\n          -  weigh  over 60 kg\n\n          -  body mass index 18 to 30 kg/m2\n\n        Exclusion Criteria:\n\n          -  any history or state of clinically significant disease\n\n          -  any gastrointestinal disease may interfere absorption of drug\n\n          -  any history of hypersensitivity to prasugrel or other drug\n\n          -  any history of taking herbal medication within 30 days before dosing or taking\n             prescription medication within 14 days before dosing or taking over the counter drug\n             within 7 days before dosing\n\n          -  taking investigational drug within 60 days before dosing\n\n          -  transfused within 30 days or  donated blood within 60 days before dosing\n\n          -  Positive serology test ( Hepatitis B surface antigen (HBs Ag), HIV, HCV)\n\n          -  Clinically significant finding in laboratory result or electrocardiogram result"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02075268", 
            "org_study_id": "PRAS-AM", 
            "secondary_id": "2014-0064"
        }, 
        "intervention": {
            "arm_group_label": "10 mg, 30 mg", 
            "description": "prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.", 
            "intervention_name": "prasugrel", 
            "intervention_type": "Drug", 
            "other_name": "Effient 10 mg tablet will be used as study drug."
        }, 
        "intervention_browse": {
            "mesh_term": "Prasugrel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Korean", 
            "Healthy", 
            "Male"
        ], 
        "lastchanged_date": "February 28, 2014", 
        "location": {
            "contact": {
                "email": "mjk0326@gmail.com", 
                "last_name": "MI Jo Kim, MD", 
                "phone": "82-2-3010-4622"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Hyeong-Suk Lim, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Single Dose Study to Characterize the Pharmacokinetics and Pharmacodynamics of Prasugrel in Healthy Male Adult Subjects", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "plasma R-138727 and R-95913 concentrations", 
            "safety_issue": "No", 
            "time_frame": "predose, 10 min, 15 min, 25 min, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 4 h, 6 h, 8 h, 12 h and 24 h after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02075268"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Hyeong-Seok Lim", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Maximal platelet aggregation will be measured by light transmission test", 
            "measure": "Maximal platelet aggregation", 
            "safety_issue": "No", 
            "time_frame": "predose, 15 min, 0.5 h, 1 h, 2 h, 4 h, 8 h, 24 h, 48 h and 72 h after dosing"
        }, 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}